206 related articles for article (PubMed ID: 10627463)
1. Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules.
Barrow RT; Healey JF; Gailani D; Scandella D; Lollar P
Blood; 2000 Jan; 95(2):564-8. PubMed ID: 10627463
[TBL] [Abstract][Full Text] [Related]
2. Anti-factor VIII inhibitor alloantibodies recognizing the A2 domain in the human factor VIII heavy chain poorly bind to porcine factor VIII.
Sawamoto Y; Shima M; Tanaka I; Nakai H; Kamisue S; Scandella D; Yoshioka A
Int J Hematol; 1997 Feb; 65(2):151-8. PubMed ID: 9071819
[TBL] [Abstract][Full Text] [Related]
3. In hemophilia A and autoantibody inhibitor patients: the factor VIII A2 domain and light chain are most immunogenic.
Scandella DH; Nakai H; Felch M; Mondorf W; Scharrer I; Hoyer LW; Saenko EL
Thromb Res; 2001 Mar; 101(5):377-85. PubMed ID: 11297754
[TBL] [Abstract][Full Text] [Related]
4. Immunoblot cross-reactivity of factor VIII inhibitors with porcine factor VIII.
Koshihara K; Qian J; Lollar P; Hoyer LW
Blood; 1995 Sep; 86(6):2183-90. PubMed ID: 7662967
[TBL] [Abstract][Full Text] [Related]
5. Antigenicity of putative phospholipid membrane-binding residues in factor VIII.
Barrow RT; Healey JF; Jacquemin MG; Saint-Remy JM; Lollar P
Blood; 2001 Jan; 97(1):169-74. PubMed ID: 11133757
[TBL] [Abstract][Full Text] [Related]
6. Mapping factor VIII inhibitor epitopes using hybrid human/porcine factor VIII molecules.
Lollar P
Haematologica; 2000 Oct; 85(10 Suppl):26-8; discussion 28-30. PubMed ID: 11187866
[TBL] [Abstract][Full Text] [Related]
7. Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization.
Scandella D; Mattingly M; de Graaf S; Fulcher CA
Blood; 1989 Oct; 74(5):1618-26. PubMed ID: 2477082
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the human factor VIII A2 inhibitor epitope by alanine scanning mutagenesis.
Lubin IM; Healey JF; Barrow RT; Scandella D; Lollar P
J Biol Chem; 1997 Nov; 272(48):30191-5. PubMed ID: 9374501
[TBL] [Abstract][Full Text] [Related]
9. Structural basis for the decreased procoagulant activity of human factor VIII compared to the porcine homolog.
Lollar P; Parker ET
J Biol Chem; 1991 Jul; 266(19):12481-6. PubMed ID: 1905722
[TBL] [Abstract][Full Text] [Related]
10. Hybrid human-porcine factor VIII proteins partially escape the inhibitory effects of anti-factor VIII inhibitor alloantibodies having A2 or C2 domain specificity.
Mizumachi K; Nakajima Y; Shimonishi N; Furukawa S; Ogiwara K; Takeyama M; Nogami K
Haemophilia; 2024 Jan; 30(1):140-150. PubMed ID: 38058226
[TBL] [Abstract][Full Text] [Related]
11. Coagulant properties of hybrid human/porcine factor VIII molecules.
Lollar P; Parker ET; Fay PJ
J Biol Chem; 1992 Nov; 267(33):23652-7. PubMed ID: 1429706
[TBL] [Abstract][Full Text] [Related]
12. The comparative immunogenicity of human and porcine factor VIII in haemophilia A mice.
Healey JF; Parker ET; Barrow RT; Langley TJ; Church WR; Lollar P
Thromb Haemost; 2009 Jul; 102(1):35-41. PubMed ID: 19572065
[TBL] [Abstract][Full Text] [Related]
13. Residues 484-508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIII.
Healey JF; Lubin IM; Nakai H; Saenko EL; Hoyer LW; Scandella D; Lollar P
J Biol Chem; 1995 Jun; 270(24):14505-9. PubMed ID: 7540171
[TBL] [Abstract][Full Text] [Related]
14. The cDNA and derived amino acid sequence of porcine factor VIII.
Healey JF; Lubin IM; Lollar P
Blood; 1996 Dec; 88(11):4209-14. PubMed ID: 8943856
[TBL] [Abstract][Full Text] [Related]
15. The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate Study Groups.
Prescott R; Nakai H; Saenko EL; Scharrer I; Nilsson IM; Humphries JE; Hurst D; Bray G; Scandella D
Blood; 1997 May; 89(10):3663-71. PubMed ID: 9160671
[TBL] [Abstract][Full Text] [Related]
16. Highly conserved antigenic structure of the factor VIII C2 domain in some mammals.
Ori J; Tanaka I; Kubota Y; Shima M; Matsumoto T; Yoshida K; Sakurai Y; Yoshioka A
Int J Hematol; 2005 Nov; 82(4):351-6. PubMed ID: 16298830
[TBL] [Abstract][Full Text] [Related]
17. Structural model of porcine factor VIII and factor VIIIa molecules based on scanning transmission electron microscope (STEM) images and STEM mass analysis.
Mosesson MW; Fass DN; Lollar P; DiOrio JP; Parker CG; Knutson GJ; Hainfeld JF; Wall JS
J Clin Invest; 1990 Jun; 85(6):1983-90. PubMed ID: 2112158
[TBL] [Abstract][Full Text] [Related]
18. Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor.
Suzuki T; Arai M; Amano K; Kagawa K; Fukutake K
Thromb Haemost; 1996 Nov; 76(5):749-54. PubMed ID: 8950785
[TBL] [Abstract][Full Text] [Related]
19. Frequency and epitope specificity of anti-factor VIII C1 domain antibodies in acquired and congenital hemophilia A.
Kahle J; Orlowski A; Stichel D; Healey JF; Parker ET; Jacquemin M; Krause M; Tiede A; Schwabe D; Lollar P; Königs C
Blood; 2017 Aug; 130(6):808-816. PubMed ID: 28507083
[TBL] [Abstract][Full Text] [Related]
20. Residues Glu2181-Val2243 contain a major determinant of the inhibitory epitope in the C2 domain of human factor VIII.
Healey JF; Barrow RT; Tamim HM; Lubin IM; Shima M; Scandella D; Lollar P
Blood; 1998 Nov; 92(10):3701-9. PubMed ID: 9808564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
